Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
AssigneeTapimmune, Inc.
InventorRobert Z. Florkiewicz
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells.
Claims21
A chimeric nucleic acid molecule, comprising a multiplex translation initiation (MTI) sequence-comprising a 5′-portion of a human FGF2 gene, wherein the 5′-portion of the human FGF2 gene comprises (i) an AUG translation initiation site and (ii) a sequence comprising from about 123 nucleotides to about 385 nucleotides upstream of the AUG translation initiation site, wherein the sequence upstream of the AUG translation initiation site comprises one to four translationally active non-AUG translation initiation sites in frame with the AUG translation initiation site, wherein the MTI is operatively linked in frame to a nucleic acid molecule encoding a fusion protein comprised of a plurality of polypeptides and the MTI allows the production of more than one mole of fusion protein per mole of mRNA.
Dependencies are inferred from the claim text.